Virally delivered Channelrhodopsin-2 Safely and Effectively Restores Visual Function in Multiple Mouse Models of Blindness

• Published in: Molecular therapy Vol. 19; no. 7; pp. 1220 - 1229
• Main Authors: Doroudchi, M Mehdi, Greenberg, Kenneth P, Liu, Jianwen, Silka, Kimberly A, Boyden, Edward S, Lockridge, Jennifer A, Arman, A Cyrus, Janani, Ramesh, Boye, Shannon E, Boye, Sanford L, Gordon, Gabriel M, Matteo, Benjamin C, Sampath, Alapakkam P, Hauswirth, William W, Horsager, Alan
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.07.2011; Elsevier Limited; Nature Publishing Group
• Subjects: Animals; Arrestin - metabolism; Behavior; Biodistribution; Blindness - genetics; Blindness - metabolism; Blindness - therapy; Carrier Proteins - genetics; Carrier Proteins - metabolism; Cells; Dependovirus; Electrophysiology; Gene therapy; Glial Fibrillary Acidic Protein; Immunohistochemistry; Leukocyte Common Antigens - metabolism; Light; Mice; Microscopy, Confocal; Mutation; Nerve Tissue Proteins - metabolism; Neurosciences; Original; Photoreceptors; Physiology; Proteins; Retina; Retina - metabolism; Vectors (Biology); Vision, Ocular - genetics; Vision, Ocular - physiology; Los Angeles California; California; United States > US; Massachusetts
• ISSN: 1525-0016; 1525-0024
• DOI: 10.1038/mt.2011.69

Previous work established retinal expression of channelrhodopsin-2 (ChR2), an algal cation channel gated by light, restored physiological and behavioral visual responses in otherwise blind rd1 mice. However, a viable ChR2-based human therapy must meet several key criteria: (i) ChR2 expression must be targeted, robust, and long-term, (ii) ChR2 must provide long-term and continuous therapeutic efficacy, and (iii) both viral vector delivery and ChR2 expression must be safe. Here, we demonstrate the development of a clinically relevant therapy for late stage retinal degeneration using ChR2. We achieved specific and stable expression of ChR2 in ON bipolar cells using a recombinant adeno-associated viral vector (rAAV) packaged in a tyrosine-mutated capsid. Targeted expression led to ChR2-driven electrophysiological ON responses in postsynaptic retinal ganglion cells and significant improvement in visually guided behavior for multiple models of blindness up to 10 months postinjection. Light levels to elicit visually guided behavioral responses were within the physiological range of cone photoreceptors. Finally, chronic ChR2 expression was nontoxic, with transgene biodistribution limited to the eye. No measurable immune or inflammatory response was observed following intraocular vector administration. Together, these data indicate that virally delivered ChR2 can provide a viable and efficacious clinical therapy for photoreceptor disease-related blindness.